<DOC>
	<DOCNO>NCT01705977</DOCNO>
	<brief_summary>The purpose study enhance exist knowledge regard side effect belimumab give lupus medicine adult active systemic lupus erythematosus ( SLE ) . This study mainly focus collect information serious event common may see long-term treatment . These event include death , serious infection infection interest , cancer , serious mental health problem , include depression suicide , serious infusion hypersensitivity reaction . This study do help understand treatment belimumab increase risk type event . This study also see patient receive belimumab lupus medicine reduce use steroid , prednisone , 1 year .</brief_summary>
	<brief_title>Belimumab Assessment Safety SLE</brief_title>
	<detailed_description>Study participant receive standard therapy SLE addition receive study drug , either placebo ( active medicine ) belimumab . The controlled period study 52 week . The random assignment study `` 1 1 '' mean participant equal chance receive belimumab placebo . After completion 52-week study period , participant contact phone annually 4 year assess health status . Following 52-week controlled period , participant wish continue treatment belimumab may able prescribe commercially available belimumab . If belimumab commercially available participant 's country , participant may able receive belimumab separate continuation protocol .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis SLE American College Rheumatology ( ACR ) criterion . Active SLE disease . Autoantibodypositive . On stable SLE treatment regimen may include corticosteroid ( example , prednisone ) , antimalarial ( example , hydroxychloroquine ) and/or immunosuppressant ( example , azathioprine , methotrexate , mycophenolate ) . Key Pregnant nursing . Have receive treatment follow : belimumab , either market product investigational agent ; B cell target therapy ( example , rituximab ) past year ; biological agent ( example , adalimumab , etanercept , infliximab , anakinra ) past 90 day . Have receive live vaccine within past 30 day . Have severe active lupus kidney disease . Have severe active central nervous system ( CNS ) lupus . Current past positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Belimumab</keyword>
</DOC>